Loading...
•
Dec 31, 2024
Ocular Therapeutix Q4 2024 Earnings Report
Ocular Therapeutix reported a wider net loss for Q4 2024, with increased revenues and higher R&D expenses.
Key Takeaways
Ocular Therapeutix saw revenue growth in Q4 2024 but reported a higher net loss due to increased research and development expenses. The company maintains a strong cash position and does not plan to raise additional capital in 2025.
Revenue increased to $17.1 million in Q4 2024, up from $14.8 million in Q4 2023.
Net loss widened to $48.4 million due to increased R&D expenses.
Cash balance reached $392.1 million, expected to fund operations into 2028.
No plans to raise additional capital this year.
Revenue by Segment
Forward Guidance
Ocular Therapeutix remains focused on advancing its pipeline while maintaining a strong cash position, with upcoming regulatory milestones expected in 2025.
Positive Outlook
- Cash balance expected to fund operations into 2028.
- No plans to raise additional capital in 2025.
- Regulatory feedback for AXPAXLI in NPDR and DME expected in 1H 2025.
- Strong retention rates in SOL-1 trial for wet AMD.
- Potential accelerated registration timelines due to SOL-1 and SOL-R adjustments.
Challenges Ahead
- Net loss increased significantly due to rising R&D costs.
- Higher operating expenses impact profitability.
- SOL-1 trial primary endpoint data delayed to Q1 2026.
- Revenue growth offset by higher gross-to-net provisions.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...